VKTX - Viking Therapeutics' Investigational Oral Obesity Drug Shows Reduced Weight In Small Study | Benzinga
Tuesday, Viking Therapeutics Inc (NASDAQ:VKTX) released results from the company’s Phase 1 multiple ascending dose (MAD) trial of an oral tablet formulation of VK2735 in development for metabolic disorders such as obesity.
The 28-day MAD study results highlight signs of clinical activity following treatment with oral VK2735.
Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 5.3%.
Cohorts receiving VK2735 also demonstrated reductions in mean body weight relative ...